Prevention of cancer chemotherapy-induced nausea and vomiting

The prevention of cancer chemotherapy-induced nausea and vomiting refers to prophylactic intervention against emesis and stomach discomfort triggered by antineoplastic drug administration in oncology patients

The prevention of cancer chemotherapy-induced nausea and vomiting refers to prophylactic intervention against emesis and stomach discomfort triggered by antineoplastic drug administration in oncology patients Clinically, chemotherapy-induced emesis is classified into acute phases (occurring within the first 24 hours of cytotoxic administration) and delayed phases (persisting beyond 24 hours up to several days), with severity directly tied to the inherent emetogenic risk of the therapeutic regime...

These adverse effects involve coordinated signaling across the gastrointestinal tract and the central nervous system, particularly mediated by the release of neuroactive substances like serotonin and substance P in the gut and the chemoreceptor trigger zone

These adverse effects involve coordinated signaling across the gastrointestinal tract and the central nervous system, particularly mediated by the release of neuroactive substances like serotonin and substance P in the gut and the chemoreceptor trigger zone

Clinically, chemotherapy-induced emesis is classified into acute phases (occurring within the first 24 hours of cytotoxic administration) and delayed phases (persisting beyond 24 hours up to several days), with severity directly tied to the inherent emetogenic risk of the therapeutic regimen

Prophylaxis aims to maintain systemic hydration, electrolyte stability, and functional nutritional status while ensuring patient compliance with antineoplastic regimens